STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

Rhea-AI Summary
Astellas Pharma to present new research results at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Summary
Pfizer amends supply agreement with US government for Paxlovid and updates Full-Year 2023 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pfizer's VELSIPITY receives FDA approval for ulcerative colitis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
Rhea-AI Summary
Pfizer's BRAFTOVI + MEKTOVI combination therapy receives FDA approval for the treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
Pfizer to present data on its infectious disease portfolio at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has declared a $0.41 fourth-quarter 2023 dividend on its common stock. The dividend will be payable on December 4, 2023, to shareholders of record on November 10, 2023. This marks the 340th consecutive quarterly dividend paid by Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
dividends
Rhea-AI Summary
Ginkgo Bioworks collaborates with Pfizer to discover RNA-based drug candidates, receiving an upfront payment and potential milestone payments up to $331 million. Ginkgo's RNA technology aims to create novel RNA constructs for more effective treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
Rhea-AI Summary
Pfizer broadens its respiratory vaccines portfolio with the addition of ABRYSVO recommended by CDC for maternal immunization against RSV. The recommendation reinforces the impact of vaccines in protecting infants from severe complications. ABRYSVO is also recommended for adults 60 years and older to prevent RSV disease. PREVNAR 20® is recommended for pneumococcal disease prevention among adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Pfizer CEO to speak at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
Rhea-AI Summary
Pfizer's LITFULO receives marketing authorization in Europe to treat severe alopecia areata in individuals 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Pfizer Inc.

OTC:PFE

PFE Rankings

PFE Stock Data

146.43B
5.64B
0.05%
69.93%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.